Gel Column Agglutination Test system Market - Global Forecast 2025-2032

The Gel Column Agglutination Test system market is evolving rapidly, propelled by innovations that drive safety, efficiency, and precision in immunohematology diagnostics. Decision-makers seeking clarity on competitive dynamics and technological advancements will find actionable intelligence here, supporting strategic responses to market developments.

Market Snapshot: Gel Column Agglutination Test System Growth and Trends

The gel column agglutination test system market reached USD 3.50 billion in 2024 and is expected to increase to USD 3.73 billion in 2025. Projected to expand at a CAGR of 6.73%, the market is set to attain USD 5.89 billion by 2032. Growth is underpinned by heightened demand for advanced blood compatibility testing, ongoing automation, and strengthening supply chains across regions.

Scope & Segmentation

This report delivers a comprehensive breakdown of the gel column agglutination test system market, analyzing product, application, end user, and regional trends for precise strategic planning.

• Test Types: Includes antibody screening (three-cell panel, two-cell panel), crossmatch (electronic, manual), grouping (forward, reverse), and identification (extended phenotyping, panel identification).
• End Users: Spans private and public blood banks, diagnostic laboratories within hospitals and reference settings, secondary and tertiary care hospitals, academic institutes, and pharmaceutical companies.
• Product Categories: Covers consumables such as gel columns and reagent cards, as well as instruments including automated and semi-automated systems.
• Applications: Encompasses immunohematology for blood transfusion, pretransfusion testing, autoimmune disorder and infectious disease diagnostics, academic research, and clinical trials.
• Sample Types: Considers plasma (cryoprecipitate, fresh frozen plasma), red cells (packed, washed), and whole blood processed as citrated or EDTA blood.
• Blood Group Systems: Includes ABO subtypes (A, AB, B, O), Duffy, Kell (K1, K2), Kidd, MNS, and Rh antigens (C, c, D, E, e).
• Regions Covered: Americas (including United States, Canada, Latin America), Europe, Middle East & Africa (United Kingdom, Germany, France, and others), and Asia-Pacific (China, India, Japan, Australia, among others).
• Key Companies: Profiles Ortho Clinical Diagnostics Holdings plc, Bio-Rad Laboratories, Inc., Grifols, S.A., Thermo Fisher Scientific Inc., Danaher Corporation, Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Immucor, Inc., Diagast, and Abacus Diagnostica Ltd.

Key Takeaways for Senior Decision-Makers

• Recent advancements in gel matrix design and reagent formulations are delivering increased assay precision, supporting hospitals and blood banks in delivering reliable patient outcomes.
• The integration of automated platforms, digital imaging, and standardized algorithms is optimizing laboratory efficiency while reducing human error and result subjectivity.
• Strategic investments in local production and nearshore supply sources are helping mitigate risks associated with shifting trade policies and supply fluctuations.
• Emerging multiplex and digital assays are positioned to streamline workflows, allowing simultaneous detection of multiple antigens and enhanced analytical sensitivity.
• Vendors are focusing on modular and scalable solutions to address the needs of mid-sized laboratories, emphasizing technical support, interoperability, and post-sale services.

Tariff Impact: Navigating 2025 U.S. Policy Changes

Recent U.S. tariff changes on imported reagents and components have increased production costs for some manufacturers. In response, companies are adjusting sourcing strategies, forging new partnerships, and streamlining logistics to maintain timely deliveries to clinical settings. Regional manufacturing investments and advocacy efforts are fostering greater market resilience.

Methodology & Data Sources

This research employs a hybrid methodology, combining direct interviews with laboratory leaders and procurement managers, rigorous secondary source validation, and industry-standard analytical frameworks. Robust quality assurance measures deliver reliable market insights for executive strategy development.

Why This Report Matters

• Enables business leaders to align investment and technology adoption strategies with emerging market and regulatory dynamics.
• Highlights actionable opportunities in automation, supply chain management, and clinical innovation for sustained revenue growth.
• Delivers in-depth competitor intelligence and trend analysis, supporting long-term planning within highly regulated laboratory environments.

Conclusion

The gel column agglutination test system market is shaped by evolving technology, regional supply dynamics, and regulatory frameworks. This report provides a robust foundation for strategic decision-making, helping stakeholders optimize operations and advance immunohematology diagnostics in diverse care settings.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.